Passionately committed to addressing the serious threat of antibiotic resistance

The Challenge: According to the Centers for Disease Control and Prevention, at least 2 million people become infected with bacteria that are resistant to antibiotics each year in the United States. We believe that new antibacterials for gram-negative bacterial infections are desperately needed.

Our People: We have deep expertise in the discovery, development and commercialization of new antibacterial drugs, including a fundamental expertise in the relationship between chemical structure and gram-negative potency. In addition, our interdisciplinary teams made up of seasoned professionals enable us to design and conduct large, global clinical trials.

Our Approach: We are committed to identifying and developing product candidates to treat multi-drug resistant (MDR) gram-negative infections. We have in-depth knowledge about the relationship between compound structure and potency against gram-negative bacteria through our work on multiple antibiotic classes. This expertise has allowed us to identify and build a portfolio of product candidates for the treatment of infections due to MDR gram-negative pathogens.

Learn more about our approach to discovering and developing gram-negative product candidates.